Top
image credit: Unsplash

NewAmsterdam Pharma and Frazier LifeSciences announce merger agreement

July 26, 2022

Via: PMLiVE

Upon closing of the transaction, a newly formed holding company, NewAmsterdam Pharma Company NV, will be led by Michael Davidson, chief executive officer of the company.

The Dutch biotech will receive approximately $235m from a private placement led by Frazier Healthcare Partners and Bain Capital Life Sciences and funds held in Frazier’s trust account.

The proceeds from this transaction, combined with the upfront payment of $123m received from NewAmsterdam’s recently announced licensing agreement with the Menarini Group and the company’s existing cash, would bring the NewAmsterdam’s total cash reserve to around $470m when the deal closes in the second half of 2022.

Read More on PMLiVE